These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

679 related items for PubMed ID: 23306360

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan.
    Hoshi SL, Seposo X, Shono A, Okubo I, Kondo M.
    Vaccine; 2019 Jun 12; 37(27):3588-3597. PubMed ID: 31153691
    [Abstract] [Full Text] [Related]

  • 28. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Rothberg MB, Virapongse A, Smith KJ.
    Clin Infect Dis; 2007 May 15; 44(10):1280-8. PubMed ID: 17443464
    [Abstract] [Full Text] [Related]

  • 29. Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.
    Le P, Rothberg MB.
    JAMA Intern Med; 2018 Feb 01; 178(2):248-258. PubMed ID: 29297049
    [Abstract] [Full Text] [Related]

  • 30. Budget-Impact Analysis of Alternative Herpes Zoster Vaccine Strategies: A U.S. HMO Perspective.
    Graham J, Mauskopf J, Kawai K, Johnson KD, Xu R, Acosta CJ.
    J Manag Care Spec Pharm; 2016 Jul 01; 22(7):872-88. PubMed ID: 27348287
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Sponsorship Bias in Base-Case Values and Uncertainty Bounds of Health Economic Evaluations? A Systematic Review of Herpes Zoster Vaccination.
    Bilcke J, Verelst F, Beutels P.
    Med Decis Making; 2018 Aug 01; 38(6):730-745. PubMed ID: 29799803
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The epidemiologic and economic impact of varicella and herpes zoster vaccination in South Korea: A mathematical modelling study.
    Kim S, Choi JK, Suh J, Park SH, Lee J.
    Vaccine; 2024 Jul 25; 42(19):4046-4055. PubMed ID: 38762358
    [Abstract] [Full Text] [Related]

  • 36. Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine.
    Pieters Z, Ogunjimi B, Beutels P, Bilcke J.
    Pharmacoeconomics; 2022 Apr 25; 40(4):461-476. PubMed ID: 35094374
    [Abstract] [Full Text] [Related]

  • 37. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM, van Ballegooijen M, Habbema JD.
    J Natl Cancer Inst; 2009 Aug 05; 101(15):1083-92. PubMed ID: 19571256
    [Abstract] [Full Text] [Related]

  • 38. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.
    Curran D, Van Oorschot D, Varghese L, Oostvogels L, Mrkvan T, Colindres R, von Krempelhuber A, Anastassopoulou A.
    Hum Vaccin Immunother; 2017 Oct 03; 13(10):2213-2221. PubMed ID: 28708959
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old.
    Van Oorschot D, Anastassopoulou A, Poulsen Nautrup B, Varghese L, von Krempelhuber A, Neine M, Lorenc S, Curran D.
    Hum Vaccin Immunother; 2019 Oct 03; 15(1):34-44. PubMed ID: 30130448
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.